Top

Published in:

01-08-2017 | 2016 SSAT Plenary Presentation

Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival

Authors: Matteo Donadon, Kelly Hudspeth, Matteo Cimino, Luca Di Tommaso, Max Preti, Paolo Tentorio, Massimo Roncalli, Domenico Mavilio, Guido Torzilli

Published in: Journal of Gastrointestinal Surgery | Issue 8/2017

Abstract

Introduction

Cancer heterogeneity and degree of intra-tumoral immune cells represent variables affecting overall survival (OS). The present study investigated the impact of natural killer (NK) and T cells infiltrating colorectal liver metastases (CLM) in patients undergoing hepatectomy after neoadjuvant chemotherapy.

Methods

The frequencies of intra-tumoral, marginal, and peritumoral CD3+ T and NKp46+ NK cells were determined for 121 patients. OS was assessed in relation to prognostic factors.

Results

At univariate analysis, several variables, including T and N of the primary tumor, metachronous CLM, radiological response, and higher density of intra-tumoral CD3+ T cell (>1%/mm²) and of NKp46+ NK cells (>1 cell/mm²), were associated with OS. Only increased frequencies of intra-tumoral CD3+ T cells (p = 0.005) and NKp46+ NK cells (p = 0.004) correlated with OS at multivariate analysis. The logistic regression revealed that metachronous CLM (OR = 2.781; p = 0.002), the use of an epidermal growth factor receptor inhibitor (OR = 3.891; p = 0.001), and radiological response (OR = 3.219; p = 0.001) were associated with higher infiltration of these cells.

Conclusions

High frequencies of NK and T cells in response to chemotherapy predict OS in CLM patients. These findings provide important insights that can help physicians to choose the best treatment option and adopt more predictive follow-up strategies for patients with CLM.

Available only for authorised users

Cucchetti A, Ferrero A, Cescon M, Donadon M, Russolillo N, Ercolani G et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015;22:1908–14.CrossRefPubMed

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371(9617):1007–16.CrossRefPubMedPubMedCentral

Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225–39.CrossRefPubMedPubMedCentral

Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014;25:1018–25.CrossRefPubMed

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–83.CrossRefPubMedPubMedCentral

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18.CrossRefPubMedPubMedCentral

Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–62.CrossRefPubMed

Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247:125–35.CrossRefPubMed

Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012;4:283–301.PubMedPubMedCentral

10.

House AK, Watt AG. Survival and the immune response in patients with carcinoma of the colorectum. Gut 1979;20:868–74.CrossRefPubMedPubMedCentral

11.

Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009;10:877–84.CrossRefPubMed

12.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960–4.CrossRefPubMed

13.

Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318–24.CrossRefPubMed

14.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491–4.PubMed

15.

Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16:2524–30.CrossRefPubMed

16.

Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013;20:946–55.CrossRefPubMed

17.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186–92.CrossRefPubMed

18.

Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999;163:2314–21.PubMed

19.

Hata K, Van Thiel DH, Herberman RB, Whiteside TL. Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology 1991;14:495–503.CrossRefPubMed

20.

Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M et al. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 2016;66:40–50.CrossRefPubMed

21.

Lee WS, Kang M, Baek JH, Lee JI, Ha SY. Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol 2013;20:697–702.CrossRefPubMed

22.

Belghiti J, Clavien P, Gadzijev E, Garden JO, Lau W, Makuuchi M et al. The Brisbane 2000 terminology of liver anatomy and resections. International Hepato Pancreato Biliary World Congress - HBP 2000;2:333–9.

23.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications—A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004;240:205–13.CrossRefPubMedPubMedCentral

24.

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Jnci-J Natl Cancer I 2014;106(6) dju124.

25.

Torzilli G. An Atlas (First Edition). Springer, Milan. 2014:280.

26.

Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006;43:S54–62.CrossRefPubMed

27.

Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Annals of Oncology 2007;18:299–304.CrossRefPubMed

28.

Tanis E, Julie C, Emile JF, Mauer M, Nordlinger B, Aust D et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer 2015;51:2708–17.CrossRefPubMed

29.

Marquardt N, Beziat V, Nystrom S, Hengst J, Ivarsson MA, Kekalainen E et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol 2015;194:2467–71.CrossRefPubMed

30.

Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 2009;124:2589–96.CrossRefPubMed

31.

Ito Y, Correll K, Zemans RL, Leslie CC, Murphy RC, Mason RJ. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-alpha/EGFR signaling. Am J Physiol Lung Cell Mol Physiol 2015;308:L1178–88.CrossRefPubMedPubMedCentral

32.

Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMed

33.

Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998;46(3):167–73.CrossRefPubMed

34.

Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13(21):6419–28.CrossRefPubMed

35.

Arjaans M, Schroder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 2016; 19:21247–58.

36.

Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014;15:601–11.CrossRefPubMed

37.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.CrossRefPubMed

38.

Garrido G, Lorenzano P, Sanchez B, Beausoleil I, Alonso DF, Perez R et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immun. 2007;56:1701–10.CrossRef

Title: Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival
Authors: Matteo Donadon
Kelly Hudspeth
Matteo Cimino
Luca Di Tommaso
Max Preti
Paolo Tentorio
Massimo Roncalli
Domenico Mavilio
Guido Torzilli
Publication date: 01-08-2017
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 8/2017
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-017-3446-6

At a glance: The STEP trials

Springer Medicine

Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2017

Differences in Effectiveness and Use of Robotic Surgery in Patients Undergoing Minimally Invasive Colectomy

The Mucocele of the Gallbladder

Domino Reconstruction of the Portal Vein Using the External Iliac Vein and an ePTFE Graft in Pancreatic Surgery

A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors

Laparoscopic Gastrojejunostomy for Patients with Unresectable Gastric Cancer with Gastric Outlet Obstruction

Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases